Entries |
Document | Title | Date |
20080214549 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors - The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) | 09-04-2008 |
20080221109 | PESTICIDAL SUBSTITUTED THIOETHERS - The invention relates to the use of thioether derivatives of formula (I) wherein: R | 09-11-2008 |
20080275050 | Pyridazine Compound and Use Thereof - A pyridazine compound represented by the formula (1): | 11-06-2008 |
20080318959 | Compounds that Inhibit Hiv Particle Formation - The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV. | 12-25-2008 |
20090005384 | Method for Producing Adsorptive Porous Body - The present invention relates to a method for producing a 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one adsorptive porous material characterized by treating a porous material with a halogen-containing organic solvent in which 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one is dissolved. The production method of the present invention is simple and easy, and the obtained adsorptive porous material is excellent in dissolution properties of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one. | 01-01-2009 |
20090042888 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors - The present invention describes pyridazinone compounds of formula I | 02-12-2009 |
20090069332 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1): | 03-12-2009 |
20090131443 | METHOD FOR PREVENTION AND/OR TREATMENT OF RHEUMATOID ARTHRITIS - The invention provides a method for the prevention and/or treatment of rheumatoid arthritis, characterized in that the method comprises administering an IL-1β inhibitor and a calcineurin inhibitor, and a preventive and/or therapeutic medicine for rheumatoid arthritis including an IL-1β inhibitor and a calcineurin inhibitor in combination. | 05-21-2009 |
20090181973 | Medicinal composition comprising 3-alkoxy-6-allylthiopyridazines for prevention or treatment of cancer of the pancreas - The present invention relates to a medicinal composition for preventing or treating pancreatic cancer, comprising 3-alkoxy-6-allylthiopyridazine or a pharmaceutically acceptable salt thereof as an effective ingredient. An MTT assay, to assess the viability of cells, and flow cytometric analysis, to measure apoptotic cell death, were performed, and the results, which revealed that the compound and pharmaceutically acceptable salts thereof have preventive and therapeutic activity against pancreatic cancer, are presented herein. | 07-16-2009 |
20090203701 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - A medicament having excellent therapeutic and prophylactic effects on rheumatoid arthritis is provided. | 08-13-2009 |
20090209542 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are compounds of the Formula I | 08-20-2009 |
20090221588 | FUNGICIDAL COMPOSITIONS - A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of Formula (I) or a compound of Formula (II) wherein R | 09-03-2009 |
20090233934 | Pyrazinecarboxamide Derivatives and Plant Disease Controlling Agents Containing the Same - The present invention provides the compounds represented by the general formula (I): | 09-17-2009 |
20090270398 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formula I) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 10-29-2009 |
20090270399 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1): | 10-29-2009 |
20090281106 | PROPHYLACTIC AND/OR THERAPEUTIC METHOD FOR RHEUMATOID ARTHRITIS - The present invention provides a prophylactic and/or therapeutic agent for rheumatoid arthritis comprising 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and leflunomide in combination. | 11-12-2009 |
20090298835 | NOVEL SCAFFOLDS FOR ALPHA-HELIX MIMICRY - Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins. | 12-03-2009 |
20090306081 | Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds - The invention provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. The invention also provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound or a pharmaceutically acceptable salt thereof and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. | 12-10-2009 |
20090318455 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS - Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. | 12-24-2009 |
20100004247 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 - The present invention relates to a therapeutic combination comprising a MEK inhibitor and an Aurora kinase inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a therapeutic combination comprising a MEK inhibitor and an Aurora kinase inhibitor; a combination product comprising a MEK inhibitor and an Aurora kinase inhibitor, a kit of parts comprising a MEK inhibitor and an Aurora kinase inhibitor; use of a therapeutic combination, combination product or kit of parts in the treatment of cancer; a method of treating cancer comprising administering the therapeutic combination, combination product or kit of parts to a patient. The therapeutic combination and methods of the invention are also useful in the treatment of conditions in which the inhibition of MEK and/or Aurora kinase is beneficial. | 01-07-2010 |
20100009991 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS - The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like. | 01-14-2010 |
20100016324 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE - There are disclosed pharmaceutical compositions for topical administration or for use in mesotherapy, containing a PDE3 inhibitor as active ingredient, and their use in the treatment of cellulite. | 01-21-2010 |
20100041661 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 02-18-2010 |
20100063053 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are compounds of the Formulas I and V | 03-11-2010 |
20100075972 | AGENT FOR TREATMENT OF MULTIPLE SCLEROSIS - To provide a preventive and/or therapeutic drug for multiple sclerosis, which has high efficacy against multiple sclerosis, which exhibits excellent safety, and which can be orally administered. | 03-25-2010 |
20100113457 | NOVEL PYRIDAZINE DERIVATIVES - The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R | 05-06-2010 |
20100286150 | LEVOSIMENDAN FOR USE IN TREATING CHRONIC VALVULAR DISEASE - A method for the treatment of chronic valvular disease (CVD) in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of levosimendan or a pharmaceutically acceptable salt thereof. Levosimendan was shown to significantly reduce mortality and to significantly improve quality of life in dogs suffering from chronic valvular disease. | 11-11-2010 |
20110065710 | Insecticidal N-(Heteroarylalkyl)Alkanediamine Derivatives - Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, R | 03-17-2011 |
20110237595 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS - The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ischaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula (I): | 09-29-2011 |
20110281876 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses compounds of formula: | 11-17-2011 |
20110301166 | METHOD FOR THE PREVENTION OF THROMBOEMBOLIC DISORDERS - A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention. | 12-08-2011 |
20120010207 | Chemical Compounds - The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. | 01-12-2012 |
20120071483 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE - The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate cell stress response for treating said disease. | 03-22-2012 |
20120135995 | FUNGICIDAL DIPHENYL-SUBSTITUTED PYRIDAZINES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, | 05-31-2012 |
20130131067 | PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition, containing a carboxamide compound represented by formula (I): | 05-23-2013 |
20130137691 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The invention relates to compounds of formula (I): | 05-30-2013 |
20130137692 | PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition containing a pyridazine compound represented by formula (I): | 05-30-2013 |
20130261125 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS - The present invention provides a compound of the Formula I, or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R | 10-03-2013 |
20130267520 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS - The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general formula (I), where R | 10-10-2013 |
20130303541 | ARYLOXY DIHALOPROPENYL ETHER COMPOUNDS AND USES THEREOF - The present invention discloses an aryloxy dihalopropenyl ether compound with the structure shown as general formula (I), of which the group definitions can be seen in the specification. The present invention also discloses the use of the compound with general formula (I) as an insecticide in the agricultural field and an insecticidal composition using the compound with general formula (I) as an active component. | 11-14-2013 |
20140213591 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 07-31-2014 |
20140378461 | NOVEL COMPOUNDS - Compounds of the formula (I), in which the substituents are as defined in claim | 12-25-2014 |
20150119397 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 04-30-2015 |
20150291529 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 10-15-2015 |
20150299138 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS - This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders. | 10-22-2015 |
20150374689 | Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass - Methods of (i) reducing morbidity and/or mortality in a human patient undergoing cardiac surgery; (ii) preventing, or reducing the risk of development of, LCOS in a human patient undergoing cardiac surgery; or (iii) reducing the risk of, intensity of, or occurrence of, one or more postoperative adverse events in a human patient undergoing cardiac surgery. The methods can involve (a) a first period of administering to the patient levosimendan for about 1 hour, in which the administration of levosimendan during the first period is initiated: (i) before skin incision for the cardiac surgery, and (ii) at an infusion dose of about 0.2 μg/kg/min; and (b) a second period of administering to the patient levosimendan for about 23 hours, in which the administration of levosimendan during the second period is initiated at an infusion dose of about 0.1 μg/kg/min. | 12-31-2015 |
20170231987 | LEVOSIMENDAN FOR USE IN THE TREATMENT OF MOTOR NEURON DISEASES (E.G. ALS) | 08-17-2017 |